BTMD offers multi-bagger recovery upside if Asteria supply normalizes, but the market is discounting recall fallout, leverage, and leadership instability.
Overview
biote Corp. operates a differentiated hormone optimization platform that helps independent clinics launch and scale cash-pay bioidentical hormone replacement therapy offerings. The company combines practitioner training, certification, software, administrative support, and pellet supply into a turnkey model that has built meaningful stickiness, evidenced by **practitioner retention above 91%** and a network of more than 9,200 certified practitioners serving roughly 400,000 active patients. The long-term opportunity is supported by favorable demographics, with menopause and andropause remaining materially undertreated across the U.S. market.
Near-term fundamentals, however, have been disrupted by a January 2026 voluntary Class II recall at Asteria Health involving estradiol sterile pellets. That event pressured first-quarter 2026 revenue, margins, and sales execution, while also increasing reliance on higher-cost third-party manufacturing. Even so, management reaffirmed 2026 guidance for **revenue above $190 million and Adjusted EBITDA above $38 million**, implying confidence that supply normalization and second-half recovery remain achievable. The stock screens optically cheap at about **0.9x EV/Sales and 4.7x EV/EBITDA** on 2026 guidance, well below the 3.1x peer EV/Sales average. The key debate is whether the discount properly reflects leverage, quality-control risk, and CEO turnover, or whether it creates an attractive recovery opportunity if Asteria stabilization and commercial traction materialize.